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Abstract
Background: The Estradiol-Dihydrotestosterone model of prostate cancer (PC) showed how the
interaction of hormones with specific hormone receptors affected apoptosis. The same hormone
can produce different effects, depending on which hormone receptor it interacts with.
Model: This model proposes that the first step in the development of most PC and breast cancer
(BC) occurs when aromatase converts testosterone to estradiol (E2). A sufficiently high enough
local level of E2 results in telomerase activity. The telomerase activity allows cell division and may
lead to BC or PC, which will proliferate if the rate of cell division is greater than the rate of cell
death. The effect of hormones on their hormone receptors will affect the rate of cell death and
determine whether or not the cancer proliferates.
Conclusion: By minimizing bcl-2 and maximizing apoptotic proteins, new systemic treatments for
BC and PC can be developed that may be more effective than existing treatments.
Background
The Estradiol-Dihydrotestosterone (E-D) model [1] of
prostate cancer (PC) describes how PC works at the level
of hormone receptors. In this model, no hormone is
"good" or "bad", but the effect of each hormone is deter-
mined by its interaction with its hormone receptors. Each
hormone receptor has an effect on apoptosis, or pro-
grammed cell death. Table 1 summarizes this model, with
↑ representing upregulation and ↓ representing downreg-
ulation. Although the exact mechanism of how the intra-
cellular androgen receptor (iAR) is able to counter the
effects of the membrane androgen receptor (mAR) is not
known, for diagrammatic purposes, the process is repre-
sented in Table 1 as downregulation. This model can be
expanded and extended to encompass breast cancer (BC)
as well.
Model
Model description
Aromatase (Aro) is an enzyme which converts testoster-
one (T) to estradiol (E2). If the Aro activity is high
enough, a process is started that may result in BC or PC.
High local levels of E2 result in human telomerase pro-
duction and activity. If the rate of growth (RG) is greater
than the rate of cell death (RD), then these cells will pro-
liferate and cancer may result. Telomerase activity was suf-
ficient to transform human cell lines that ordinarily have
limited life spans into immortalized cell lines [2].
This model makes the assumption that the effects of hor-
mones on hormone receptors are the same for BC and PC
unless there is evidence to the contrary. Table 2 shows the
properties of the hormone receptors as proposed in the
extended E-D model.
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Estrogen receptors
E2 upregulated both human telomerase mRNA and
human telomerase activity in normal prostate epithelial
cells, benign prostate hyperplasia, and the PC cell lines
LNCaP, DU145, and PC-3 [3]. In the presence of E2, a vec-
tor that resulted in the overproduction of estrogen recep-
tor-α (ER-α) showed an increase in telomerase promoter
activity for PC and for the BC cell line MCF-7. However,
in the presence of E2, a vector that resulted in the overpro-
duction of ER-β showed an increase in telomerase pro-
moter activity in PC, but not in BC. Increasing ER-α would
result in an increase in ER-α homodimers, a decrease in
ER-β homodimers, and an increase in ER-αβ heterodim-
ers. Similarly, increasing ER-β would result in an increase
in ER-β homodimers, a decrease in ER-α homodimers,
and an increase in ER-αβ heterodimers. This is all consist-
ent with ER-αβ heterodimers upregulating telomerase
activity in prostate epithelial cells and PC. However,
another possibility is that both ER-α homodimers and ER-
β homodimers upregulate telomerase activity. If het-
erodimers were not involved, then ER-α should not be
needed to increase telomerase activity. However, mice
lacking ER-α do not develop PC [4]. Assuming that the
reason for this is that without ER-α, no telomerase activity
could occur in the prostate epithelial cells, then this
would be consistent with ER-αβ heterodimers upregulat-
ing telomerase activity. It is still possible that ER-α
homodimers could upregulate telomerase activity as well.
When 4-hydroxytamoxifen (OHT) was added to LNCaP
cells transfected with the expression vector for ER-α, tel-
omerase activity was upregulated, but not when trans-
fected with the expression vector for ER-β instead [3]. This
is consistent with OHT upregulating telomerase activity in
PC by acting as an agonist for ER-α homodimers. The
extended E-D model takes the view that ER-α homodim-
ers are responsible for the increase in telomerase activity
in BC and PC because if ER-α receptors alone were able to
increase telomerase activity, then ordinary levels of E2
might lead to telomerase activity. The important point is
that for both BC and PC, a local increase in the level of E2
results in an increase in telomerase activity.
One of the requirements for any cancer to grow is limitless
replicative potential [5]. Ordinarily, cells are capable of a
limited number of divisions due to their telomere length,
which shortens following each division. Cell division in
the absence of sufficient telomere length usually results in
senescence or apoptosis due to accumulation of the apop-
totic protein p53 [6]. Mutations in p53 allow cell division
to occur in the absence of sufficient telomere length, but
usually result in chromosomal instability that may lead to
carcinogenesis [7]. Telomeres can be lengthened by tel-
omerase activity or by alternative lengthening of telom-
eres (ALT) [8]. Telomerase activity has been found in 90%
of prostate carcinomas and 88% of ductal and lobular
breast carcinomas [9]. This is consistent with telomerase
activity being one of the first steps in almost all BC and
PC. Those without telomerase activity would be expected
to have ALT or mutations in p53.
In disease-free breast adipose tissue, Aro activity is usually
expressed at low levels due to promoter I.4 [10]. In adi-
pose tissue of BC, Aro activity is much higher due to the
presence of promoters I.3 and II. Cyclic adenosine 3',5'-
monophosphate (cAMP) analogues switch the promoters
to I.3 and II for human adipose fibroblasts (HAFs) [11].
Exposing HAFs to BC cell-conditioned medium induced
promoter II activity in a process independent of cAMP
[10]. Cell-conditioned media of normal breast epithelial
cells, liver cancer cells, and PC cells all failed to induce
promoter II activity in HAFs. This is consistent with one or
more factors found in BC being responsible for the
increased Aro activity in HAFs. E2 was found in signifi-
cantly higher concentrations in BC than in normal breast
Table 1: E-D model of prostate cancer
Hormone receptor Property
Membrane androgen receptor ↑apoptotic proteins
↑bcl-2
↑calreticulin
Intracellular androgen receptor ↓apoptotic proteins
↓bcl-2
Estrogen receptor-αβ heterodimer ↑telomerase activity
Estrogen receptor-α↑ bcl-2
Estrogen receptor-β↓ bcl-2
Table 2: Extended E-D model of breast cancer and prostate 
cancer
Hormone receptor Property
Membrane androgen receptor ↑apoptotic proteins
↓bcl-2 (BC only)
↑bcl-2 (PC only)
↓AS3
↑Ca++ influx
Intracellular androgen receptor ↓apoptotic proteins
↓bcl-2
↑AS3
↓Ca++ influx
↑calreticulin
Estrogen receptor-αβ heterodimer ↑telomerase activity (PC only)
Estrogen receptor-α homodimer ↑telomerase activity
Estrogen receptor-α↑ bcl-2
Estrogen receptor-β↓ bcl-2
Membrane estrogen receptor ↑bcl-2
Progesterone receptor A ↑bcl-2
Progesterone receptor B ↓bcl-2
Membrane progesterone receptor ↓bcl-2Theoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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tissue [12]. The level of E2 found in the BC of postmeno-
pausal women was similar to that found in the BC of pre-
menopausal women. The local level of E2 was 10 times
higher for BC in postmenopausal women than the level
found in their blood plasma or normal breast tissue [13].
This is consistent with most BC starting due to the produc-
tion of one or more factors in the breast epithelial cells
which have the capability of inducing promoter II activity
in the surrounding adipose tissue. More research is
needed to discover how promoter I.3 activity is induced
and to learn what factors are responsible for inducing pro-
moter II activity.
Aro activity was not observed [14] in normal prostate epi-
thelial cells, but was observed in the PC cell lines LNCaP,
DU145, and PC-3. The level of Aro activity in PC was in
the same range as Aro activity in BC. Mice lacking the Aro
gene never develop PC. Also, Aro activity was detected
[15] in three of four PC tumors that were tested. The occa-
sional PC tumor lacking Aro activity can be explained by
the PC having ALT, mutated p53, or a mutation that pro-
motes telomerase activity without requiring Aro activity.
These findings are consistent with most PC starting due to
the permanent activation of the Aro gene.
ER-α and ER-β are known to tend to counteract each other
[16]. E2 increased the production of bcl-2 in MCF-7 [17],
an ER-α positive cell line of BC. This increase was negated
by the addition of OHT, a known antagonist to ER-α in
breast tissue [18]. This is consistent with ER-α being
responsible for upregulating bcl-2. By applying the princi-
ple of ER-β acting in opposition to ER-α, then ER-β should
downregulate bcl-2 in BC.
Mice with a genetic mutation that knocks out ER-β have
an overexpression of bcl-2 in their ventral prostate [19].
This is consistent with ER-β downregulating bcl-2 in PC.
In accordance with the principle of ER-α acting in opposi-
tion to ER-β, then ER-α should upregulate bcl-2 in PC.
Membrane estrogen receptor (mER) upregulated bcl-2 in
the BC line T47D [20]. All of the above is consistent with
mER and ER-α upregulating bcl-2 and ER-β downregulat-
ing bcl-2. More research is needed on the specific hor-
mone receptors to verify and to quantify these findings.
Progesterone receptors
Mifepristone (RU-486), a drug that is antagonistic to pro-
gesterone receptor A (PRA), decreased bcl-2 production in
LNCaP [21], an androgen dependent PC (ADPC) cell line.
Production of bcl-2 was decreased even further when pro-
gesterone (P) was added in addition to RU-486. This is
consistent with PRA upregulating bcl-2 and either proges-
terone receptor B (PRB), membrane progesterone receptor
(mPR), or both, downregulating bcl-2. However, further
experiments must be done on other cell lines, since
LNCaP has been shown to have mutated iAR that binds to
P [22] and iAR downregulates bcl-2. The extended E-D
model takes the view that both PRB and mPR downregu-
late bcl-2 in PC, but further experimentation must be
done to verify this.
The mutations BRCA1 and BRCA2 have a striking lack of
PRB expression in normal breast cells [23]. BRCA1 muta-
tions result in an increased chance of developing BC for
women, but not men, and an increased chance of devel-
oping PC for men. BRCA2 mutations result in an
increased chance of developing BC for men and for
women and an increased chance of developing PC for
men [24]. According to the extended E-D model, the
decreased amount of PRB should result in decreased
downregulation of bcl-2, resulting in higher levels of bcl-
2 being present. While this would not in itself cause BC or
PC, it does increase the likelihood that RG > RD if an initial
cancer cell arises.
The fact that men with BRCA1 mutations do not have an
increased chance of developing BC can be explained by
the decreased downregulation of bcl-2 that results from
the loss of PRB being offset by men's high levels of T
which results in both mAR and iAR significantly downreg-
ulating bcl-2. If a high enough level of T is present, it is
possible that no net increase in bcl-2 would occur in spite
of the absence of PRB. In PC, high levels of T end up with
iAR downregulating bcl-2, but with mAR upregulating
bcl-2, which results in more bcl-2 being present than is the
case for BC. Since women have a much lower level of T
than men do, the increase in bcl-2 that results from the
loss of PRB would probably not be offset by the downreg-
ulation of bcl-2 by the androgen receptors. This is consist-
ent with BRCA1 increasing the level of bcl-2 in the breast
tissue of women but not of men. Since BRCA2 mutations
increase the chance of developing BC for both men and
women, this implies that there is another factor present in
BRCA2 mutations which decreases RD or increases RG in
addition to the elimination of PRB. Further research is
needed to clarify this point.
Mice which were BRCA1/p53 deficient all developed BC,
unless they were treated with RU-486, in which case none
of the mice developed BC [25]. This is consistent with bcl-
2 production increasing in response to P for BRCA1 muta-
tions due to PRA upregulating bcl-2 and the absence of
PRB downregulating bcl-2. Therefore, the fact that BC pro-
liferated in the absence of PRB means that RG > RD. The
fact that RU-486 prevented BC development is consistent
with mPR downregulating bcl-2. This is because in the
presence of RU-486, there is no PRA or PRB available for
P to bind to, and since this prevents BC, then RG < RD. If
mPR upregulated bcl-2, then P would have caused anTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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increase in bcl-2, which might have resulted in some of
the mice developing BC if RD became low enough. Assum-
ing mPR downregulates bcl-2, but not as strongly as PRA
upregulates bcl-2, then in the absence of RU-486, P would
have resulted in an increase in bcl-2 and therefore an
increased incidence of BC due to the decrease in RD,
whereas in the presence of RU-486, P would have resulted
in a decrease in bcl-2 and therefore a decreased incidence
of BC due to the increase in RD, which what was in fact
observed. Also, it is likely that the combined BRCA1/p53
deficiency still resulted in the same number of initial BC
cells arising in all of the mice, but since RG < RD in the pres-
ence of RU-486, the BC was unable to proliferate.
The inferences drawn by combining the above experi-
ments are consistent with the conclusion of the extended
E-D model that PRA upregulates bcl-2, whereas PRB and
mPR downregulate bcl-2. However, further testing is
needed to conclusively prove these points.
Androgen receptors
By using T-BSA, which is known to bind to mAR but not
to iAR, it was shown that mAR upregulates [26] bcl-2 in
PC, but downregulates [20] it in BC. mAR upregulated the
apoptotic protein Bad in BC [20] and Fas in PC [26]. Also,
upregulation of the apoptotic proteins U19 and ALP1 in
PC has been attributed to mAR due to the rapidity of their
production immediately after androgen deprivation ther-
apy (ADT) is ended [1]. For both BC and PC, flutamide,
an antagonist of iAR, was used as a control. The effect of
T-BSA on mAR was the same in the presence and in the
absence of flutamide, further confirming that T-BSA
bound to mAR but not to iAR. In both BC and PC, mAR
exhibited rapid steroid effects typical of non-genomic ster-
oid hormone actions, whereas iAR exhibited the slow
effects typical of genomic steroid hormone actions, which
typically take hours.
5α-dihydrotestosterone (DHT) downregulated bcl-2 in
the PC cell line LNCaP-FGC [27] and in the BC cell line
ZR-75-1 [28]. This downregulation disappeared when an
antagonist of iAR was added. All of this is consistent with
iAR downregulating bcl-2.
Androgens inhibited cell proliferation in the BC cell line
MCF7-AR1 [29], which has approximately five times more
iAR than the BC cell line MCF7 does. In the presence of
androgens plus bicalutamide, an antagonist to iAR, no
inhibition of cell proliferation was observed. Androgens
upregulated AS3, a protein which shuts off cell prolifera-
tion, in MCF7-AR1 [30]. This is consistent with iAR upreg-
ulating AS3.
The PC cell line LNCaP-FGC has high levels of iAR [31].
High physiological levels of androgens caused prolifera-
tive shutoff of LNCaP-FGC [30]. There was a strong corre-
lation between this proliferative shutoff and AS3
expression. The PC cell line LNCaP 104-R2 had its growth
inhibited by T, but stimulated by T plus finasteride (F)
[32]. F inhibits 5-α reductase type II (5AR2), which is an
enzyme that converts T to DHT. LNCaP 104-R2 also has
high levels of iAR [33]. This is all consistent with iAR
upregulating AS3 in BC and PC. If mAR downregulates
AS3, and ordinarily there is a balance between iAR and
mAR, then it would require an imbalance that results in
an overexpression of iAR with regards to mAR in order for
AS3 to be upregulated. This would explain why LNCaP
104-R2 upregulated AS3 after being exposed to T. The
high levels of iAR would have created the imbalance that
led to AS3 being upregulated. When F was added, DHT
conversion from T was blocked, so instead of DHT, T
became the ligand for iAR. Since T binds to iAR with an
affinity five times less than that of DHT [34], the necessary
imbalance was no longer present and inhibition of
growth no longer occurred. Further research is needed to
determine exactly what effect mAR has on AS3 produc-
tion.
Calcium ion (Ca++) influx increased when T-BSA was
added to PC cells [35]. The observed increase in Ca++
influx is consistent with mAR upregulating Ca++ influx,
since T-BSA binds to mAR but not to iAR. The fact that T-
BSA caused Ca++ influx, whereas T does not, is consistent
with iAR downregulating Ca++  influx. Ca++  influx also
occurs during ADT [36]. If the absence of androgen allows
Ca++ influx to occur, then it is likely that one or more pro-
teins are responsible for preventing Ca++ influx. This is
consistent with iAR upregulating proteins which are
responsible for preventing Ca++ influx.
Calreticulin (Cal) is a protein that binds to Ca++ and pre-
vents apoptosis due to Ca++ overload. In the E-D model,
the position was taken that Cal was upregulated by mAR,
however, in the extended E-D model, the position is that
Cal is upregulated by iAR. In the fully grown prostate, F
slightly inhibited Cal production [37], which is consistent
with iAR upregulating Cal. It is not clear what the affinity
of T-BSA, T, or DHT is to mAR, but equal concentrations
of these hormones resulted in identical levels of apoptosis
in the PC cell line DU145 after 24 hours [26]. This is con-
sistent with T and DHT binding to mAR with somewhat
similar affinities, but further research is needed. Since
DHT binds with greater affinity than T to iAR, then the
decrease in Cal production in the presence of F is consist-
ent with iAR upregulating Cal. Further research is needed
to determine what effect mAR has on Cal regulation.
Prevention
In designing protocols for preventing BC and PC, every
effort should be made to avoid potential long term sideTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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effects, while still increasing RD as much as possible, so
that RG < RD for any early stage cancer cells that may
already be present. This means that, for safety concerns,
no drugs should be used which block hormone receptors,
since, until proven otherwise, it must be assumed that
every hormone receptor has some purpose in the overall
health of the body. Also, hormone levels should be kept
within their physiological limits until evidence is pro-
duced that shows that it is safe to go outside of those lim-
its. Within these constraints, the goal is to maximize the
production of apoptotic proteins upregulated by mAR
and to minimize the production of bcl-2.
One way to minimize bcl-2 production would be to max-
imize the activity of PRB and mPR while minimizing the
activity of PRA. However, since no hormone has yet been
discovered that does this, then P has to be considered
instead. P should be increased to the maximum safe phys-
iological amount appropriate for the gender of the indi-
vidual being treated, unless testing shows a genetic
makeup that results in an increase in bcl-2 in the breast or
prostate epithelial cells in response to P, such as in the
case of BRCA1 or BRCA2 mutations.
Another way to minimize Bcl-2 would be by using a hor-
mone that binds preferentially to ER-β over ER-α and
mER. Estriol (E3) has an affinity for ER-β which is 3.5
times greater than for ER-α, E2 has an equal affinity for
ER-α and ER-β, and estrone has an affinity for ER-α which
is 5 times greater than for ER-β[38]. This is consistent with
E3 being the preferred ligand for ER-β. However, E3 binds
to ER-β only 35% as strongly as E2 does. More research is
needed to determine whether E3, possibly in combina-
tion with a drug to block Aro in order to minimize the
local level of E2, would be helpful or not.
In order to maximize the production of apoptotic proteins
upregulated by mAR, binding to mAR should be increased
as much as possible and binding to iAR should be
decreased as much as possible. Since T and DHT seem to
have similar affinities to mAR, whereas DHT has an affin-
ity to iAR which is five times greater than T, then high T
and low DHT (HTLD) should create the desired imbal-
ance. Therefore, the serum level of bioavailable T should
be increased to the maximum safe physiological level
appropriate for the gender of the individual being treated,
while the serum level of DHT should be decreased to the
minimum physiological level necessary for maintaining
good health. Since T can be converted to E2 by Aro, the
level of E2 should be monitored and kept within normal
or low normal physiological levels. In addition to increas-
ing the apoptotic proteins upregulated by mAR, this pro-
tocol should increase Ca++  influx and decrease Cal
production, all of which should increase RD.
When LNCaP tumors were transplanted into nude mice,
four weeks of T-BSA administration resulted in a 60%
reduction in tumor volume when compared to BSA
administration alone [26]. Also, when LNCaP tumors
were transplanted into nude mice, treatment with T plus F
following intermittent androgen ablation resulted in no
change or a decrease in tumor volume for 41% of the
mice, as compared to 10% of the mice treated with T alone
[39]. This is consistent with the greatest increase in RD
occurring after full agonism of mAR along with no ago-
nism of iAR. However, if there is a great amount of ago-
nism of mAR along with a small amount of agonism of
iAR, then there would still be an increase in RD for PC if
the imbalance in the binding to the androgen receptors is
great enough. Using F to prevent DHT creates such an
imbalance, since T has an affinity which is five times less
than that of DHT to iAR. This raises the possibility that
HTLD would result in RG < RD for most early stage BC or
PC cells.
The active metabolite of vitamin D is 1,25(OH)2D3 (calci-
triol). When calcitriol bound to the vitamin D receptor
(VDR), it inhibited growth and upregulated AS3 in a
number of PC cell lines [40] and increased cell death in
BC [41] and PC [42]. Calcitriol caused cell death primarily
by a caspase-independent mitochondrial pathway in BC
[41] and in PC [42]. Also, bcl-2 inhibited the cell death
caused by calcitriol in BC [41] and in PC [42]. In some PC
cell lines, bicalutamide repressed the inhibition in growth
and upregulation of AS3 cause by calcitriol [40]. This is
consistent with the upregulation of AS3 by calcitriol being
dependent on properly functioning iAR. As part of the
prevention protocol, the serum level of calcitriol should
be increased to the maximum safe physiological level.
This may decrease RG in BC and PC, and if the level of bcl-
2 is low enough, may increase RD.
HTLD will have different effects with regards to bcl-2 pro-
duction for BC and PC. For BC, the increased amount of T
binding to mAR will result in a decrease in bcl-2 due to
increased downregulation. However, the decreased
amount of DHT binding to iAR will result in less downreg-
ulation of bcl-2 production and therefore an increase in
bcl-2. Therefore, there should not be a dramatic increase
in bcl-2 for BC as a result of HTLD.
For PC, however, the increased amount of T binding to
mAR will result in an increase in bcl-2 due to increased
upregulation and the decreased amount of DHT binding
to iAR will also result in an increase in bcl-2 due to
decreased downregulation. Therefore, for preventing PC,
more care must be used to decrease bcl-2 in other ways, if
possible. Also, large quantities of foods which contain
components which bind to ER-β with less than full ago-
nism should be avoided. This is because such componentsTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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might interfere with E2 binding to ER-β and thus reduce
the downregulation of bcl-2. For example, genistein, the
main isoflavone found in soy, increased bcl-2 in the BC
cell line MCF-7 [43].
Anecdotally, some men with PC who were taking 5AR2
inhibitors following ADT exhibited consistent increases in
PSA values associated with the introduction of large doses
of genistein, soy, tofu, modified citrus pectin, or flaxseed
into a pre-existing diet. Often this change in PSA trajectory
could be reversed by stopping that nutritional product
[44]. This is consistent with the use of 5AR2 inhibitors
resulting in an increase in bcl-2 as well as a decrease in the
downregulation of apoptotic proteins upregulated by
mAR. Ordinarily, the decrease in the downregulation of
apoptotic proteins has more of an effect than the increase
in bcl-2, as evidenced by the apoptotic effect of T-BSA.
However, if large amounts of food are ingested which
bind preferentially to ER-β, then the overall increase in
bcl-2 may decrease RD more than the apoptotic proteins
increase RD. This would be expressed by a more rapid pop-
ulation growth, which would account for the observed
increase in PSA for those men taking 5AR2 inhibitors.
Pharmacological amounts of genistein induced apoptosis
in PC cell lines by a process independent of its binding to
estrogen receptors [45]. Therefore, it is likely that physio-
logical amounts of genistein increase RD to some extent.
However, when 5AR2 inhibitors are used in conjunction
with genistein, the overall increase in bcl-2 that results
may more than offset the anticancer effects of genistein, if
any PC cells are already present. If no PC cells are present,
then ingesting phytoestrogens should help prevent PC,
since the phytoestrogens should interfere to some degree
with the ability of E2 to upregulate telomerase. Pharmaco-
logical levels of genistein did suppress telomerase activity
in the PC cell lines LNCaP and DU-145 [46].
Although in using the HTLD protocol for preventing PC,
the hormones would be kept within physiological levels,
there is still the possibility that long term use of this pro-
tocol may have some health consequences unrelated to
PC. Lean elderly men and women who have Alzheimer's
disease (AD) had lower bioavailable levels of T than those
without AD [47]. This might be due to AD causing a drop
in the level of bioavailable T, or by the low bioavailable
level of T increasing the likelihood of developing AD. T
downregulated β-amyloid peptides in vitro [48], and β-
amyloid is considered to be crucial in the pathogenesis of
AD [49]. This increases the likelihood that the decreased
levels of bioavailable T were responsible for the increased
incidences of AD. If so, then the HTLD protocol for pre-
venting BC and PC may also be helpful in preventing AD.
In a five year study for male veterans over 40 years of age,
those with low levels of T had a mortality rate of 34.9% as
compared to 20.1% for those with normal levels of T [50].
Low levels of T were defined as a level of total T below 250
ng/dL or a level of free T below 0.75 ng/dL. This raises the
possibility that the HTLD protocol for preventing PC
might also result in increased longevity for men. It is not
yet known what the relationship between T and longevity
is for women. More research is needed to fully identify all
beneficial and detrimental effects that may result from
using the HTLD protocol in men and in women.
In summary, the protocol for preventing both BC and PC
involves obtaining gender appropriate maximum safe
physiological levels of bioavailable T, maximum safe
physiological level of calcitriol, minimum safe physiolog-
ical level of DHT and normal level of E2. Maximum safe
physiological levels of P should be added except for those
individuals whose genetic makeup would not benefit
from P. If further research should determine that E3 is
helpful, then maximum safe physiological levels of E3
should be added. Also, ingesting large quantities of foods
which are known to bind to ER-β with less than full ago-
nism should be avoided. Other factors, such as nutritional
supplements or lifestyle changes which are shown to
reduce the incidence of BC and PC, can also be included.
Table 3 shows the effects of the HTLD protocol.
It is possible that the HTLD protocol might be ineffective
or even harmful depending on the mutations that may be
in some of the BC or PC already present. For example, if
there is a mutation in PC that prevents mAR from upreg-
ulating apoptotic proteins but still allows it to upregulate
bcl-2, then the HTLD protocol would be harmful. The ear-
lier this protocol is started, the less likely that any such
adverse mutations would be present.
An alternative strategy for prevention would involve all of
the steps listed above, but in place of maximizing the
upregulation of apoptotic proteins by mAR through
Table 3: HTLD Protocol
Treatment Results Effects
High T ↑apoptotic proteins
↓bcl-2 (BC only)
↑bcl-2 (PC only)
↓AS3
↑Ca++ influx
↑ RD
↑ RD
↓ RD
↑ RG
↑ RD
Low DHT ↑apoptotic proteins
↑bcl-2
↓AS3
↑Ca++ influx
↓calreticulin
↑ RD
↓ RD
↑ RG
↑ RD
↑ RD
High P ↓bcl-2 (favorable genetics) ↑ RD
High calcitriol ↑AS3
↑kill mitochondria
↓ RG
↑ RD
Lowering phytoestrogens ↓bcl-2 ↑ RDTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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HTLD, instead minimize the amount of bcl-2 present and
rely on the high serum level of calcitriol to maximize
apoptosis. For BC, the gender appropriate maximum
physiological level of bioavailable T and DHT or high T
and high D (HTHD) would reduce the production of bcl-
2 in comparison to HTLD, since DHT downregulates bcl-
2. This decrease in bcl-2 should increase the likelihood
that calcitriol would increase RD. However, it would also
eliminate the imbalance that should upregulate the apop-
totic proteins associated with mAR, which should result in
a decrease in RD. Further research is needed to determine
whether HTLD or HTHD is more effective in preventing
BC. For HTHD, there is no need to avoid ingesting phy-
toestrogens, since no 5AR2 inhibitors would be present
and therefore no decrease in bcl-2. Table 4 shows the
effects of the HTHD protocol.
For PC, the minimum safe physiological level of bioavail-
able T and the maximum safe physiological level of DHT
or low T and high D (LTHD) should reduce bcl-2 even
more than HTHD does, assuming that maximum ago-
nism of mAR is not achieved with the maximum safe
physiological level of DHT alone. This is because reducing
the level of T would reduce the overall amount of andro-
gen available to bind to mAR and mAR upregulates bcl-2
in PC. Further research is needed to determine whether
HTLD or LTHD is more effective in preventing PC. Also,
for LTHD there is no need to avoid ingesting phytoestro-
gens. Table 5 shows the effects of the LTHD protocol.
Treatment
When treating BC or PC systemically, the goal should be
to minimize bcl-2 and to maximize apoptotic proteins,
without regards to long term health risks. If the genetic
makeup of the BC or PC were known, then treatments
could be individually designed for optimal effectiveness.
However, due to the heterogeneous nature of BC and PC,
care must be taken to consider all possible mutations and,
whenever possible, to avoid using any treatment that
would ever decrease RD. Ideally, if the initial treatment is
successful, then treatment can eventually be changed to
one of the preventative protocols described previously.
Systemic hormonal manipulation is currently being used,
to a limited extent, for both PC and BC. In PC, the form of
systemic hormonal manipulation currently being used is
ADT. During ADT, downregulation of Cal coupled with
Ca++ influx may lead to apoptosis [36]. For prostate cells,
the level of apoptosis in the absence of androgen is the
same as that in the presence of androgen if ionophores are
used to cause sufficiently high Ca++ influx [51]. In the
absence of androgen, the increased amount of apoptosis
could be reduced by up to 70% through the use of Ca++
channel blockers. This is all consistent with Ca++ overload
being the cause of apoptosis during ADT. When ADT is
administered, typically nothing is done to maximize the
upregulation of apoptotic proteins or to maximize the
downregulation of bcl-2.
For BC which has ER-α present, currently systemic hormo-
nal manipulation is aimed at reducing the binding of E2
to ER-α. This is accomplished either by using tamoxifen,
in order to block the binding to ER-α, or anastrozole,
which is an antagonist to Aro, in order to reduce the
amount of E2 present in the BC cells. In both cases, bcl-2
production should be reduced, since ER-α upregulates
bcl-2. However, nothing is done to utilize any of the other
hormone receptors to further reduce bcl-2 production and
nothing is done to maximize the production of apoptotic
proteins.
There are a number of options available in searching for
the optimum treatment protocol. One consideration is
whether or not localized treatment, such as surgery,
should be done initially for BC or PC. It is known that if
surgery does not remove all cancer cells, the remaining
cancer cell population doubles at a quicker rate than it did
before the surgery [52]. Increased angiogenesis is one of
Table 5: LTHD Protocol
Treatment Results Effects
Low T ↓apoptotic proteins
↑bcl-2 (BC only)
↓bcl-2 (PC only)
↑AS3
↓Ca++ influx
↓ RD
↓ RD
↑ RD
↓ RG
↓ RD
High DHT ↓apoptotic proteins
↓bcl-2
↑AS3
↓Ca++ influx
↑calreticulin
↓ RD
↑ RD
↓ RG
↓ RD
↓ RD
High P ↓bcl-2 (favorable genetics) ↑ RD
High calcitriol ↑AS3
↑kill mitochondria
↓ RG
↑ RD
Table 4: HTHD Protocol
Treatment Results Effects
High T ↑apoptotic proteins
↓bcl-2 (BC only)
↑bcl-2 (PC only)
↓AS3
↑Ca++ influx
↑ RD
↑ RD
↓ RD
↑ RG
↑ RD
High DHT ↓apoptotic proteins
↓bcl-2
↑AS3
↓Ca++ influx
↑calreticulin
↓ RD
↑ RD
↓ RG
↓ RD
↓ RD
High P ↓bcl-2 (favorable genetics) ↑ RD
High calcitriol ↑AS3
↑kill mitochondria
↓ RG
↑ RDTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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the proposed explanations for this. If this increased rate of
population growth is shown to be at all due to an increase
in RG, then it would be more difficult to use systemic treat-
ment to achieve RG < RD following surgery. If systemic hor-
monal treatment can be shown to be sufficiently effective
in early stage treatment, it is possible that localized treat-
ment may not be necessary. However, systemic hormonal
treatment must be continued indefinitely in case any BC
or PC cells remain, whereas surgery has the possibility of
being curative. There is also the possibility that surgery
might remove cancer cells that have already mutated to
the point that systemic treatment would be ineffective on
them, so that surgery followed by systemic treatment
might be successful whereas systemic treatment without
surgery might be a failure. More research is needed to clar-
ify this point.
Men with stage T1–T2 PC, with a mean prostate specific
antigen (PSA) of 13.5, whose initial treatment was radical
prostatectomy (RP) had a PC specific death rate of 4.6%
and a 10.1% rate of distant metastases after a median of
6.2 years [53]. Men with stage T1–T3 PC, with a mean PSA
of 11.1, whose initial treatment was 13 months of ADT
utilizing a luteinizing hormone-releasing hormone ago-
nist to reduce T production, plus an antiandrogen to block
iAR, plus F to reduce DHT by inhibiting 5AR2, followed
after those 13 months by continual F only, had a PC spe-
cific death rate of 0.6% [54] and a 0.6% rate of distant
metastases [44] after a median of 6.2 years. All of the men
in this study were told to avoid ingesting large amounts of
phytoestrogens [44]. This raises the possibility that initial
systemic treatment may be a viable alternative to local
treatments for PC.
While this systemic treatment compares quite favourably
with RP, it is possible to make improvements during ADT
based on the extended E-D model. Maximum antagonism
of mAR and iAR should be used. In order to obtain the
lowest level of bcl-2 from the non-androgen receptors
(LBNAR), maximum antagonism of ER-α, mER, and PRA
should be used, as well as maximum agonism of ER-β,
PRB, and mPR. P should be used only in the presence of a
drug that blocks the conversion of P to T, since P is able to
be converted to T [55]. Also, maximum agonism of VDR
(MAV) should be used in order to increase RD by killing
mitochondria.
Incorporating these modifications should minimize the
amount of bcl-2 present while maintaining the apoptotic
forces of ADT. Further research is needed to verify that the
LBNAR protocol maintains Ca++ influx coupled with the
absence of Cal which is known to occur in ADT without
LBNAR. It is possible that some of the non-androgen
receptors are involved in the regulation of Ca++ influx and
Cal. For example, there is evidence [56] that mER upregu-
lates Ca++ influx in the PC cell line LNCaP. Table 6 shows
the effects of the enhanced ADT treatment.
Following ADT, there should be maximum agonism of
mAR coupled with maximum antagonism of iAR, or all
mAR no iAR (AMNI). AMNI should maximize the produc-
tion of the apoptotic proteins upregulated by mAR, and
should increase the level of bcl-2, since mAR upregulates
bcl-2 and iAR downregulates bcl-2. There should also be
increased Ca++ influx and decreased production of Cal. It
is possible that AMNI will not result in the same level of
apoptosis from Ca++ overload as what is seen in ADT,
since other receptors besides iAR and mAR may be
involved in Ca++  influx and Cal production. LBNAR
should be added to minimize bcl-2 production. MAV
should also be added to AMNI. This should increase RD if
the overall level of bcl-2 is low enough, but should not
increase AS3 due to the antagonism of iAR. The optimum
length of time to maintain this treatment needs to be
determined. Table 7 shows the effects of the AMNI treat-
ment.
Since the AMNI treatment may fail against PC with
mutated mAR that is unable to upregulate apoptotic pro-
teins, it should be followed by a treatment of maximum
antagonism of mAR along with maximum agonism of
iAR, or no mAR all iAR (NMAI). NMAI should increase the
production of AS3 upregulated by iAR to stop cell prolif-
eration, and should lower bcl-2 levels. LBNAR and MAV
should also be added to NMAI. In this case, MAV should
decrease RG  by increasing the production of AS3 and
increase RD, since, as opposed to AMNI, NMAI should
reduce bcl-2 production in PC. Table 8 shows the effects
of the NMAI treatment. Mutations in the iAR that bind to
E2 and P, such as exists in LNCaP, would protect the cells
against AMNI, but should be vulnerable to NMAI. NMAI
Table 6: Enhanced ADT Treatment
Treatment Results Effects
Maximum antagonism of mAR ↓apoptotic proteins
↑bcl-2 (BC only)
↓bcl-2 (PC only)
↑AS3
↓Ca++ influx
↓ RD
↓ RD
↑ RD
↓ RG
↓ RD
Maximum antagonism of iAR ↑apoptotic proteins
↑bcl-2
↓AS3
↑Ca++ influx
↓calreticulin
↑ RD
↓ RD
↑ RG
↑ RD
↑ RD
Maximum antagonism of ER-α↓ bcl-2 ↑ RD
Maximum agonism of ER-β↓ bcl-2 ↑ RD
Maximum antagonism of mER ↓bcl-2 ↑ RD
Maximum antagonism of PRA ↓bcl-2 ↑ RD
Maximum agonism of PRB ↓bcl-2 ↑ RD
Maximum agonism of mPR ↓bcl-2 ↑ RD
Maximum calcitriol ↑kill mitochondria ↑ RDTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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should be much less effective against PC with non-func-
tioning iAR, but such cells should have already undergone
apoptosis from the AMNI treatment. Incorporating both
AMNI and NMAI should maximize overall PC cell death.
For BC, the initial treatment should also be maximum
antagonism of mAR and iAR along with LBNAR and MAV.
This should be effective assuming that iAR upregulates Cal
and downregulates Ca++ influx as it does for PC. Next, the
AMNI protocol along with LBNAR and MAV should be
done. This would have similar benefits as was described
for PC, although because mAR downregulates bcl-2 in BC,
as opposed to upregulating it in PC, the RD would be
expected to be greater, since the level of bcl-2 should be
lower. Just as in PC, the NMAI protocol along with LBNAR
and MAV should be done next. This should have an equiv-
alent effectiveness against BC as it had against PC. An
additional protocol to consider for BC would be to use
maximum agonism of mAR and of iAR, or all mAR all iAR
(AMAI). When LBNAR and MAV are added, this should
have a bcl-2 level lower than for any of the other proto-
cols, but it would then be dependent on calcitriol killing
mitochondria to increase RD and upregulating AS3 to
decrease RG. Table 9 shows the effects of the AMAI treat-
ment.
More research is needed to determine the effectiveness of
these treatments and the optimal time to maintain each
treatment. For both PC and BC, if the treatments are suc-
cessful then one of the preventative protocols can then be
used.
Discussion
The protocols given for preventing and treating BC and PC
are merely suggestions based on the properties of the
extended E-D model. There are other possible alternatives
that can be tried. In the case of prevention, it is possible
that raising T to higher than physiological levels when
using HTLD may have beneficial effects. Individuals with
mutations in BRCA1 or BRCA2 may want to start a pre-
ventative protocol at an earlier age. A protocol for preven-
tion may also be applied to patients after they initially
receive localized treatment, such as surgery or radiation.
Changes in lifestyle that are shown to be useful against BC
and PC, such as diet and exercise, can be added to the pro-
tocols for prevention and treatment.
BC and PC are complex diseases, and the properties of
hormone receptors described in the extended E-D model
represent a foundation which can be built on to better
understand both diseases. Bcl-2 is chosen as the main
Table 9: AMAI Treatment
Treatment Results Effects
Maximum agonism of mAR ↑apoptotic proteins
↓bcl-2 (BC only)
↑bcl-2 (PC only)
↓AS3
↑Ca++ influx
↑ RD
↑ RD
↓ RD
↑ RG
↑ RD
Maximum agonism of iAR ↓apoptotic proteins
↓bcl-2
↑AS3
↓Ca++ influx
↑calreticulin
↓ RD
↑ RD
↓ RG
↓ RD
↓ RD
Maximum antagonism of ER-α↓ bcl-2 ↑ RD
Maximum agonism of ER-β↓ bcl-2 ↑ RD
Maximum antagonism of mER ↓bcl-2 ↑ RD
Maximum antagonism of PRA ↓bcl-2 ↑ RD
Maximum agonism of PRB ↓bcl-2 ↑ RD
Maximum agonism of mPR ↓bcl-2 ↑ RD
Maximum calcitriol ↑AS3
↑kill mitochondria
↓ RG
↑ RD
Table 7: AMNI Treatment
Treatment Results Effects
Maximum agonism of mAR ↑apoptotic proteins
↓bcl-2 (BC only)
↑bcl-2 (PC only)
↓AS3
↑Ca++ influx
↑ RD
↑ RD
↓ RD
↑ RG
↑ RD
Maximum antagonism of iAR ↑apoptotic proteins
↑bcl-2
↓AS3
↑Ca++ influx
↓calreticulin
↑ RD
↓ RD
↑ RG
↑ RD
↑ RD
Maximum antagonism of ER-α↓ bcl-2 ↑ RD
Maximum agonism of ER-β↓ bcl-2 ↑ RD
Maximum antagonism of mER ↓bcl-2 ↑ RD
Maximum antagonism of PRA ↓bcl-2 ↑ RD
Maximum agonism of PRB ↓bcl-2 ↑ RD
Maximum agonism of mPR ↓bcl-2 ↑ RD
Maximum calcitriol ↑kill mitochondria ↑ RD
Table 8: NMAI Treatment
Treatment Results Effects
Maximum antagonism of mAR ↓apoptotic proteins
↑bcl-2 (BC only)
↓bcl-2 (PC only)
↑AS3
↓Ca++ influx
↓ RD
↓ RD
↑ RD
↓ RG
↓ RD
Maximum agonism of iAR ↓apoptotic proteins
↓bcl-2
↑AS3
↓Ca++ influx
↑calreticulin
↓ RD
↑ RD
↓ RG
↓ RD
↓ RD
Maximum antagonism of ER-α↓ bcl-2 ↑ RD
Maximum agonism of ER-β↓ bcl-2 ↑ RD
Maximum antagonism of mER ↓bcl-2 ↑ RD
Maximum antagonism of PRA ↓bcl-2 ↑ RD
Maximum agonism of PRB ↓bcl-2 ↑ RD
Maximum agonism of mPR ↓bcl-2 ↑ RD
Maximum calcitriol ↑AS3
↑kill mitochondria
↓ RG
↑ RDTheoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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antiapoptotic protein to focus on in this model because it
has been shown to be extremely powerful. It prevented
apoptosis caused by calcitriol in BC [41] and in PC [42].
Also, bcl-2 is known to be able to prevent apoptosis
caused by Fas [57] and by Bad [20]. Just by increasing bcl-
2, using a vector of cDNA, LNCaP turned into an andro-
gen independent PC cell line [58]. This is consistent with
bcl-2 protecting against the apoptosis caused by ADT. The
increased chance of developing BC and PC in individuals
with either the BRCA1 or BRCA2 mutation is consistent
with the increased bcl-2 caused by the elimination of PRB
being partly responsible for the increased incidence of
cancer. Also, assuming that there is a purpose in the pat-
tern of which hormone receptors upregulate bcl-2 and
which downregulate bcl-2, then it is possible that the
same pattern may apply to other anti-apoptotic proteins
as well.
If iAR is not functional, then apoptotic proteins will be
upregulated by mAR in both BC and PC. In BC, bcl-2 will
also be downregulated, helping to further increase RD,
whereas, in PC, bcl-2 will be upregulated. In PC, this cre-
ates a situation in which the same hormone receptor
exhibits one property that increases the chance of apopto-
sis and another that decreases the chance of apoptosis.
Ordinarily, apoptosis will occur if a sufficient quantity of
androgen is present, as evidenced by the fact that T-BSA
resulted in a 60% reduction in tumor size of LNCaP trans-
planted into nude mice after one month [26]. Since mAR
downregulates bcl-2 in BC, less T should be needed in
order to achieve apoptosis in BC than in PC. This means
that for men, BC should be much less likely to occur than
in women, in part because of the higher levels of T that
men possess when compared to women. In fact, men
rarely develop BC. However, the incidence of BC increases
[59] in men who suffer from disorders related to hypoan-
drogenism.
Although telomerase activity may immortalize cells, it is
not sufficient by itself to produce cancer as evidenced by
the fact that the tissue cultures with telomerase activity did
not become cancerous [2]. It is believed that there are six
properties that a cell must acquire in order to become can-
cerous [5]. These properties are self-sufficiency in growth
signals, insensitivity to antigrowth signals, evading apop-
tosis, limitless replicative potential, sustained angiogen-
esis, and tissue invasion and metastasis. Such changes
would confer a great selective advantage when they occur
in immortalized cells growing within an organ confined
space. However, it is not clear that such changes would
confer much of an advantage to immortalized cells grow-
ing in a tissue culture.
A key prediction of the extended E-D model is that HTLD
will increase RD in both BC and PC. One experiment [39]
that highlights the power of this treatment used LNCaP
cells transplanted into nude castrated mice, then treated
with T plus F following intermittent androgen ablation.
The change in tumor volume ended up being around 5
times less than that when continual androgen ablation
was used. The proteins that are rapidly produced, presum-
ably upregulated by mAR, are only observed to be present
for a few hours following the addition of T plus F to end
the androgen ablation. In the absence of androgen abla-
tion, production of these proteins following the addition
of T plus F is not observed. This raises the possibility that
not just DHT, but also T binding to iAR is sufficient to
completely downregulate the proteins upregulated by
mAR, so that no net production of these proteins occurs.
Another possibility is that some small amount of apop-
totic proteins upregulated by mAR is continually being
produced in the presence of HTLD, and the accumulation
of these proteins might be responsible for apoptosis. Also,
due to the low DHT, there might be increased Ca++ influx
along with lowered production of Cal, which might
increase RD as well.
If the observed apoptosis was totally due to the apoptotic
proteins upregulated by mAR when initially unopposed
by downregulation from iAR, then the amount of apopto-
sis should be about the same for T and DHT. However,
when T alone was used to end androgen ablation, the
result was an average increase of 128% in tumor volume.
This was much worse than the average increase of 23% in
tumor volume observed when T plus F was used to end
androgen ablation. Also, considering that LNCaP is an
ADPC cell line, the addition of T should have resulted in
an increase in tumor volume much greater than that
observed with continual androgen ablation. The fact that
continual androgen ablation had an average increase of
114% in tumor volume means that using T alone after
androgen ablation was only a little worse than continual
androgen ablation. This difference suggests that the initial
increase in apoptotic proteins that occurred when the
faster acting mAR was active, but the slower acting iAR was
not yet active, might be responsible for the better than
expected results for T alone.
Another possibility is that the effectiveness of HTLD was
due to the low DHT caused by F, either because of a
decrease in RG or an increase in RD. However, when andro-
gen ablation plus F was used, the average increase in
tumor volume was 91%, which was a bit better than con-
tinual androgen ablation, but still much worse than
HTLD. As a result, the benefits observed from using T plus
F are consistent with an initial surge followed by a slow
continual release of apoptotic proteins due to the imbal-
ance in the binding of T to both mAR and iAR as com-
pared to the binding of T to mAR and DHT to iAR.Theoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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In order to determine the best protocol for preventing BC
and PC, the HTLD, HTHD, and LTHD protocols should be
examined for their efficacy in increasing RD for BC and PC
in animal studies as well as with various cell lines. Since it
is assumed that some BC or PC cells may be present before
treatment is started, it is important that the protocol used
have the ability to cause apoptosis or inhibit the growth of
existing BC or PC. Also, in addition to a protocol's effec-
tiveness in preventing BC and PC, its impact on quality of
life must be considered. Since the protocol will be used for
long term, a significant improvement in quality of life
might offset a slightly inferior effectiveness in preventing
BC and PC. It is also possible that alternating between the
preventative protocols might be more effective than main-
taining just one. More research is needed to examine these
possiblities.
In considering the best protocol for treating BC and PC,
the theoretical ideals were given, with no consideration to
the side effects of the treatment or whether the necessary
drugs existed and were available for human use. In prac-
tice, both of these must be considered and modifications
must be made, while trying to stay as close to the theoret-
ical ideal as possible. For example, it is known that high
levels of calcitriol cause hypercalcemia, but research is
being done [60] to develop vitamin D analogues which
are capable of being agonists to VDR while not producing
hypercalcemia.
For a model to be an accurate reflection of reality, it
should be able to explain all observed experimental
results. The extended E-D model can explain some exper-
imental findings in a straightforward manner. One exam-
ple would be the fact that both exogenous T and E2 must
be given to Noble rats in order to reproducibly induce PC
[61]. The high level of E2 would increase telomerase activ-
ity directly in the prostate epithelial cells, without the
need for Aro activity. If T were not also added, then the E2
would suppress the production of T [62], resulting in the
high RD typical of ADT. If T were used without E2, then tel-
omerase activity would occur when Aro was activated,
which would produce high local levels of E2 and telomer-
ase activity. However, for prostate epithelial cells to
express Aro activity requires either a mutation or presum-
ably a failure to methylate the portion of DNA containing
the Aro gene. Therefore, the fact that the percentage of
Noble rats that develop PC when exposed just to exoge-
nous T is much lower than the percentage that develop PC
when exposed to exogenous T plus E2 is consistent with
the extended E-D model.
Another example is that mammary epithelial proliferation
in ovariectomized rhesus monkeys occurred after three
days of treatment with tamoxifen [63]. This is consistent
with OHT upregulating telomerase activity in breast epi-
thelial cells by acting as an agonist to ER-α homodimers,
just as it does for PC. The long term effect of tamoxifen use
would depend on the values of RG and RD that result.
One example that is more problematic for the extended E-
D model to explain is the relationship between serum lev-
els of T and incidence of BC and PC. The extended E-D
model would predict that there is a separate threshold
level of bioavailable T for BC and PC, above which RG <
RD. For levels below this threshold, RG > RD and if BC or
PC develops, then it can proliferate. As bioavailable levels
of T decrease further, RD should also decrease. This should
not increase the incidence of BC or PC, but should
increase the aggressiveness of the disease. For BC, this is
because lower agonism of mAR would result in less apop-
totic proteins being upregulated, and lower agonism of
iAR would result in less AS3 being upregulated. In addi-
tion, there should be higher levels of bcl-2, since both
mAR and iAR downregulate bcl-2. The same factors would
explain the increase in PC, except that in prostate epithe-
lial cells mAR upregulates bcl-2 whereas iAR downregu-
lates bcl-2. This would result in less of an increase in bcl-
2 than occurs in breast epithelial cells. Lower levels of T
were associated with worsening clinical staging, worsen-
ing histological staging, and more poorly differentiated
adenocarcinomas for PC [64].
However, higher levels of free T are correlated with slightly
increased incidences of BC [65] and PC [66]. The higher
level of free T would mean that the intracellular level of T
should be higher than for those individuals with lower
levels of free T. The higher intracellular level of T should
result in higher local levels of E2 if Aro activity is present.
The higher level of E2 might lead to higher telomerase
activity and possibly an increase in RG, making it more
likely that RG > RD for some individuals. Another possibil-
ity is that the higher level of free T results in higher local
levels of DHT. This increase in DHT should result in
increased agonism of iAR which should result in more
downregulation of the apoptotic proteins upregulated by
mAR. If ordinarily apoptosis is caused in part by the slow
accumulation of these apoptotic proteins, then the
increased downregulation by iAR should result in a
decrease in RD, increasing the possibility that RG > RD.
Also, if the level of free T becomes low enough, then even
in the presence of Aro activity, the local level of E2 that
results would be too low to upregulate telomerase activity,
removing Aro activity as a cause for BC or PC.
More research is needed to test the properties of the
extended E-D model. Experiments concentrating on indi-
vidual hormone receptors are essential. The extended E-D
model can be expanded to include how hormone recep-
tors upregulate or downregulate other proapoptotic and
antiapoptotic proteins as they are discovered.Theoretical Biology and Medical Modelling 2007, 4:28 http://www.tbiomed.com/content/4/1/28
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Conclusion
BC and PC appear to be functionally identical, but there
are slight differences in the way each disease achieves that
functionality. The most striking difference between the
two diseases is the difference in the properties of their
mAR. In both BC and in PC, apoptosis occurs following
the loss of functionality of their iAR. However, since
women have much lower levels of T than men do, in order
to maintain the identical functionality it is necessary for
mAR to be more effective in inducing apoptosis in BC
than in PC, which in fact appears to be the case. For both
BC and PC, mAR upregulates apoptotic proteins, but for
BC, mAR also downregulates bcl-2, whereas for PC, mAR
upregulates bcl-2.
BC and PC are complex diseases, but by focusing on the
properties of the individual hormone receptors, it is pos-
sible to develop systemic protocols for prevention and
treatment. Such protocols can be augmented by any life-
style changes, such as diet and exercise, which may be
shown to be helpful.
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